The proceeds will primarily be used to fund R&D aimed at the identification and validation of protein biomarkers with the goal of finding high potential diagnostic candidates.
Christopher Hibberd, Astute Medical’s CEO, said: “This investment is an exciting event that lays the foundation for our R&D activities. We believe the participation of our lead investor De Novo Ventures demonstrates confidence in our ability to develop innovative diagnostic tests for use in acute hospital settings.”